MedPath

CagriSema Fails to Meet Primary Endpoint in Phase III Clinical Trial for Obesity

• Novo Nordisk's CagriSema failed to achieve statistically significant weight loss compared to semaglutide alone in a Phase III trial for obesity management. • The trial assessed CagriSema, a combination of cagrilintide and semaglutide, in adult participants with a BMI of 27 kg/m² or greater. • Despite the setback, Novo Nordisk remains committed to obesity treatment and is continuing to develop and evaluate new therapeutic options. • The company's stock experienced a notable decline following the announcement of the trial's outcome.

Novo Nordisk's investigational drug CagriSema did not meet its primary endpoint in a Phase III clinical trial evaluating its efficacy in treating obesity. The trial aimed to demonstrate superior weight loss with CagriSema compared to semaglutide alone, but the combination therapy failed to achieve statistical significance on this measure.
The Phase III study involved adult participants with a body mass index (BMI) of 27 kg/m² or greater, indicating overweight or obesity. Participants were administered CagriSema, which combines cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. The trial's primary endpoint was the percentage change in body weight from baseline to week 52.
While CagriSema did not meet the primary endpoint, Novo Nordisk indicated that they are continuing to analyze the data to fully understand the results. The company remains dedicated to advancing obesity treatment and is actively pursuing other therapeutic avenues. The failure to meet the primary endpoint in this trial represents a setback for Novo Nordisk's obesity pipeline.
Following the announcement of the trial results, Novo Nordisk's stock experienced a significant decline, reflecting investor concern over the future prospects of CagriSema and its potential impact on the company's obesity franchise. Further details regarding the trial's secondary endpoints and safety profile have not yet been released.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

AbbVie Reassesses Emraclidine's Future After Phase II Schizophrenia Trial Failures

AbbVie's emraclidine failed to meet primary endpoints in Phase II trials for schizophrenia, leading to a $3.5 billion impairment charge and a reevaluation of its development path.
The company is now focusing on emraclidine as an adjunctive treatment for schizophrenia and as a monotherapy for psychosis related to Alzheimer's and Parkinson's diseases.

Syros and Cassava Face Setbacks as Phase III Trial Results Disappoint Investors

Biotechnology companies Syros Pharmaceuticals and Cassava Sciences reported disappointing Phase III clinical trial results, leading to significant stock price declines. The setbacks highlight the ongoing challenges in late-stage drug development and the critical importance of clinical trial outcomes for biotech companies.

Pharma Stock Roundup: Novo Nordisk's Obesity Study Disappoints, Lilly's Zepbound Approved for Sleep Apnea

Novo Nordisk's CagriSema obesity treatment showed a 22.7% weight loss in Phase III, falling short of the anticipated 25% reduction, impacting stock prices.
Eli Lilly's Zepbound (tirzepatide) received FDA approval for moderate-to-severe obstructive sleep apnea (OSA), marking it as the first drug for obesity-related OSA.

Hengrui Pharma's HRS9531 Shows Promising Weight Loss in Phase 2 Obesity Trial

Hengrui Pharmaceuticals and Kailera Therapeutics reported positive Phase 2 results for HRS9531, a GLP-1/GIP receptor dual agonist, in overweight or obese adults.
Participants receiving the 8 mg dose of HRS9531 achieved a statistically significant 21.1% placebo-adjusted mean weight loss at 36 weeks.

Cassava Sciences' Simufilam Fails Phase III Alzheimer's Trial, Stock Plummets

Cassava Sciences' Phase III trial of simufilam in mild-to-moderate Alzheimer's disease failed to meet primary endpoints, showing no significant reduction in cognitive decline.
The company has halted its second Phase III trial and open-label extension study of simufilam, effectively ending the drug's development program.

Eyenovia's Stock Plummets After Phase III Myopia Trial Fails to Meet Primary Endpoint

Eyenovia's stock price plummeted after its Phase III CHAPERONE study, evaluating a drug-device combination for pediatric progressive myopia, failed to meet its primary endpoint.
The CHAPERONE trial assessed low-dose atropine delivered via the Optejet platform but did not demonstrate a statistically significant difference in myopia progression compared to the comparator arm.

Eyenovia's Myopia Trial Fails, Stock Plummets

Eyenovia's stock price plummeted after its Phase III CHAPERONE study for pediatric progressive myopia failed to meet the primary endpoint.
The CHAPERONE trial assessed a low-dose atropine formulation delivered via the Optejet platform but did not demonstrate a significant difference in myopia progression compared to the comparator.

Novo Nordisk's CagriSema Shows Promise in Weight Loss and Diabetes Treatment

CagriSema, Novo Nordisk's experimental drug, combines semaglutide with cagrilintide for enhanced weight loss and blood sugar regulation.
Early trials indicate CagriSema could lead to a 15.6% weight loss over 32 weeks, potentially reaching up to 25% in larger trials.

Amgen's Obesity Drug MariTide Faces Bone Density Concerns; AstraZeneca Invests $3.5B in US Expansion

Amgen's MariTide, an obesity drug, faced scrutiny after an analyst suggested a potential link to bone density loss based on Phase 1 trial data.
Lexeo Therapeutics reached an agreement with the FDA for its gene therapy LX2006 targeting Friedreich ataxia with cardiomyopathy, potentially leading to accelerated approval.

Novo Nordisk's $1bn Oral Weight Loss Drug Shows Promise but Raises Questions in Phase IIa Trial

Novo Nordisk's monlunabant, an oral cannabinoid receptor 1 inverse agonist acquired for $1bn, demonstrated statistically significant weight loss in a Phase IIa trial but raised concerns about optimal dosing.
The 10mg dose achieved a 7.1kg weight reduction compared to 0.7kg with placebo, but higher doses showed limited additional benefit while increasing dose-dependent gastrointestinal and neuropsychiatric side effects.

Reference News

[1]
NVO Stock Plunges As Obesity Drug CagriSema Misses Target In Phase III - Barchart.com
barchart.com · Dec 23, 2024

Switch Market flag for country-specific data. Right-click for chart options. Use arrows to navigate symbols.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy